Pharmacogenetics in Inflammatory Bowel Disease

  • Marla C. Dubinsky


Inflammatory Bowel Disease TPMT Activity Thiopurine Methyltransferase Thiopurine Therapy TPMT Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    US Department of Health and Human Services Food and Drug Administratio. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health, 2003.Google Scholar
  2. 2.
    Remy CN. J Biol Chem 1963:238;1078–1084.Google Scholar
  3. 3.
    Lennard L. Eur J Clin Pharmacol 1992:43;329–339.PubMedCrossRefGoogle Scholar
  4. 4.
    Lennard L, Van Loon JA, Weinshilboum RM. Clin Pharmacol Ther 1989:46;149–154PubMedCrossRefGoogle Scholar
  5. 5.
    Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. J Pediatr 1991:119;985–989.PubMedCrossRefGoogle Scholar
  6. 6.
    Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Clin Pharmacol Ther 1987:41;18–25PubMedCrossRefGoogle Scholar
  7. 7.
    Weinshilboum RM, Sladek SL. Am J Human Genet 1980:32;651–662.Google Scholar
  8. 8.
    Van Loon JA, Weinshilboum RM. Biochem Genet 1982:20;637–658.PubMedCrossRefGoogle Scholar
  9. 9.
    Woodson LC, Dunnette JH, Weinshilboum RM. J Pharmacol Exp Ther 1982:222;174–181.PubMedGoogle Scholar
  10. 10.
    Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Pharmacogenetics 1992:2;148–159.PubMedCrossRefGoogle Scholar
  11. 11.
    Coulthard SA, Howell C, Robson J, Hall AG. Blood 1998:92;2856–2862.PubMedGoogle Scholar
  12. 12.
    Honchel R, Aksoy I, Szumlanski C, Wood TC, Otterness DM, Wieben ED et al. Mol Pharmacol 1993:43;878–887.PubMedGoogle Scholar
  13. 13.
    Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D et al. DNA Cell Biol 1996:15;17–30.PubMedGoogle Scholar
  14. 14.
    Tai H-L, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF et al. Am J Hum Genet 1996:58;694–702.PubMedGoogle Scholar
  15. 15.
    Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Pharmacogenetics Genomics 2005:15;801–815.CrossRefGoogle Scholar
  16. 16.
    Hon YY. Fessing MY. Pui CH. Relling MV. Krynetski EY. Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999:8;371–376.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee FJ, Kalow W. Thiopurine S methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993:54;28–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Lancet 1990:336;225–229.PubMedCrossRefGoogle Scholar
  19. 19.
    Tai H-L, Fessing MY, Bonten EJ, Yanishevsky Y, d’Azzo A, Krynetski EY et al. Pharmacogenetics 1999:9;641–650.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang L, Sullivan W, Toft D, Weinshilboum R. Pharmacogenetics 2003:13;555–564.PubMedCrossRefGoogle Scholar
  21. 21.
    Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003:111;1133–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Neurath MF, Kiesslich R, Teichgraber U, Fischer C, Hofmann U, Eichelbaum M, Galle PR, Schwab M. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn’s disease. Clin Gastroenterol & Hepatol 2005:3;1007–14CrossRefGoogle Scholar
  23. 23.
    Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000:118;705–7PubMedCrossRefGoogle Scholar
  24. 24.
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase:possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmac 1995:39;456–9.Google Scholar
  25. 25.
    Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW. Olsalazine and 6-mercaptopurine-related bone marrow suppression:a possible drug-drug interaction. Clin Pharmacol & Ther 1997:464–475.Google Scholar
  26. 26.
    Dewitt O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther 2002:16;79–85.CrossRefGoogle Scholar
  27. 27.
    Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000:118;1025–1030.PubMedCrossRefGoogle Scholar
  28. 28.
    Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn’s disease. J Clin Gastroenterol 2002:35;240–244.PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Aliment Pharmacol Ther 2002:16;389–398.PubMedCrossRefGoogle Scholar
  30. 30.
    Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Preliminary Evidence Suggests That 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP Resistance in Patients with Inflammatory Bowel Disease. Gastroenterology 2002:122;904–915.PubMedCrossRefGoogle Scholar
  31. 31.
    Cuffari C, Thèorêt Y, Latour S, Seidman EG. 6-mercaptopurine metabolism in Crohn’s disease:correlation with efficacy and toxicity. Gut 1996:39;401–406.PubMedCrossRefGoogle Scholar
  32. 32.
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001:48;642–646.PubMedCrossRefGoogle Scholar
  33. 33.
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006:130;47–53.CrossRefGoogle Scholar
  34. 34.
    Weinshilboum R. New Engl J Med 2003:348;529–537.PubMedCrossRefGoogle Scholar
  35. 35.
    Weinshilboum R, Wang L. Nat Rev Drug Disc 2004b:3;739–748.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Marla C. Dubinsky
    • 1
  1. 1.David Geffen School of Medicine, UCLA, Director Pediatric IBD Center, Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations